Answers are grounded in this paper and cite their sources.
and preclinical studies eliciting the potency of TEXs in inducing effective anti-tumor responses and recently modified strategies further improving TEX-vaccination efficacy. We interpret the available data as TEXs becoming a lead in cancer vaccination based on tumor antigen-selective high immunogenicity.
No takes yet. Share an insight, caveat, or question.
Naseri et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: